Abstract
To avoid the use of carbapenems, alternatives such as cephamycin, piperacillin-tazobactam, and others are suggested for the treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections. The aim of this study was to evaluate the frequency and the feasibility of antimicrobial de-escalation for ESBL-PE-related infections. A prospective observational, bi centric cohort study was conducted. All patients with ESBL-PE infections were included. De-escalation was systematically suggested if patients were clinically stable and the isolate was susceptible to possible alternatives. Seventy-nine patients were included: 36 (45.6%) were children, 27 (34.1%) were hospitalized in intensive care units, and 37 (47%) were immunocompromised. Urinary tract infections, pneumonia, and catheter-related bloodstream infections accounted for 45.6%, 19%, and 10%, respectively, of the cohort. Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were the three most frequent causative organisms isolated. On day 5, 47 (59.2%) of the patients were still receiving carbapenems. Antimicrobial resistance (44.7%), infection relapse (26.9%), and clinical instability (19.2%) were the most important reasons for not prescr...Continue Reading
References
Jun 1, 1992·Chest·R C BoneW J Sibbald
Feb 11, 2003·Critical Care Medicine·Marc LeoneClaude Martin
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Mathias W R PletzHartmut Lode
Jan 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emilio BouzaPatricia Muñoz
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Jun 6, 2007·Intensive Care Medicine·Elpis GiantsouKonstantinos Manolas
Mar 29, 2008·American Journal of Infection Control·Kurt B StevensonJulie E Mangino
Sep 24, 2008·Archives of Internal Medicine·Jesús Rodríguez-BañoAlvaro Pascual
Dec 26, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinJohn G Bartlett
Jun 28, 2011·Infection·S MeierB Hasse
Jul 20, 2011·Diagnostic Microbiology and Infectious Disease·Daryl J HobanRobert Badal
Aug 27, 2011·Clinics in Chest Medicine·Michael S Niederman, Vasiliki Soulountsi
Jan 20, 2012·The Journal of Antimicrobial Chemotherapy·J RobertUNKNOWN Surveillance de la prescription des antibiotiques (SPA) Group
Mar 21, 2012·Critical Care Medicine·Sarah HeenenJean-Louis Vincent
Apr 18, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R CantónUNKNOWN European Network on Carbapenemases
Oct 24, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nan-Yao LeeWen-Chien Ko
Apr 25, 2013·Antimicrobial Agents and Chemotherapy·Pilar RetamarUNKNOWN ESBL-REIPI/GEIH Group
Jul 11, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T DeloryP Lesprit
Apr 18, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E WeissUNKNOWN 'De-escalation' Study Group
Citations
Jun 28, 2016·The Journal of Infection·A BoucherO Leroy
Nov 5, 2016·Diagnostic Microbiology and Infectious Disease·Qi NiYibing Peng
Oct 8, 2016·Postgraduate Medicine·Mazen S BaderAnnie A Brooks
Dec 31, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Anthony Ayodeji AdegokeThor Axel Stenström
Jan 26, 2018·PloS One·Fouad MadhiRobert Cohen
Sep 4, 2021·International Journal of Microbiology·Patrick Eberechi AkpakaPadman Jayaratne